News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
703,668 Results
Type
Article (41721)
Company Profile (473)
Press Release (661474)
Section
Business (208445)
Career Advice (2010)
Deals (35954)
Drug Delivery (97)
Drug Development (83367)
Employer Resources (169)
FDA (16343)
Job Trends (15049)
News (352209)
Policy (32994)
Tag
Academia (2619)
Alliances (50711)
Alzheimer's disease (1307)
Approvals (16294)
Artificial intelligence (155)
Bankruptcy (361)
Best Places to Work (11783)
Biotechnology (355)
Breast cancer (195)
Cancer (1416)
Cardiovascular disease (117)
Career advice (1677)
Cell therapy (302)
Clinical research (66481)
Collaboration (511)
Compensation (267)
COVID-19 (2602)
C-suite (115)
Data (1418)
Diabetes (181)
Diagnostics (6229)
Earnings (86122)
Employer resources (147)
Events (113499)
Executive appointments (405)
FDA (17045)
Funding (453)
Gene therapy (213)
GLP-1 (635)
Government (4418)
Healthcare (19025)
Infectious disease (2695)
Inflammatory bowel disease (118)
Interviews (309)
IPO (16625)
Job creations (3696)
Job search strategy (1430)
Layoffs (445)
Legal (7939)
Lung cancer (203)
Manufacturing (215)
Medical device (13362)
Medtech (13367)
Mergers & acquisitions (19491)
Metabolic disorders (487)
Neuroscience (1650)
NextGen Class of 2024 (6738)
Non-profit (4537)
Northern California (1726)
Obesity (277)
Opinion (202)
Parkinson's disease (102)
Patents (122)
People (57829)
Phase I (20863)
Phase II (29343)
Phase III (21695)
Pipeline (523)
Postmarket research (2598)
Preclinical (8937)
Radiopharmaceuticals (252)
Rare diseases (283)
Real estate (5999)
Regulatory (22128)
Research institute (2405)
Resumes & cover letters (351)
Southern California (1501)
Startups (3747)
United States (15718)
Vaccines (581)
Weight loss (199)
Date
Today (19)
Last 7 days (516)
Last 30 days (2466)
Last 365 days (36404)
2024 (36244)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54923)
2019 (47419)
2018 (35697)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (731)
Arizona (204)
Asia (38678)
Australia (6432)
California (3944)
Canada (1470)
China (315)
Colorado (177)
Connecticut (189)
Europe (84348)
Florida (542)
Georgia (136)
Illinois (401)
Indiana (228)
Maryland (651)
Massachusetts (3111)
Michigan (177)
Minnesota (298)
New Jersey (1132)
New York (1112)
North Carolina (803)
Northern California (1726)
Ohio (148)
Pennsylvania (941)
South America (1106)
Southern California (1501)
Texas (571)
Utah (110)
Washington State (415)
703,668 Results for "atossa therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Societal CDMO Enters Agreement With Atossa Therapeutics to Provide Clinical Trial Services (CTS) for Innovative Selective Estrogen Receptor Modulator
Societal CDMO, Inc. today announced that it has been selected by Atossa Therapeutics (Nasdaq: ATOS ) to provide a range of its Clinical Trial Services (CTS) offerings focused on Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen.
May 23, 2023
·
5 min read
Business
Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial
Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative™ (“Quantum Leap”) today announced that six patients have been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in the ongoing Phase 2 I-SPY 2 clinical trial.
June 28, 2023
·
6 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
BioForest
Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial
Atossa Therapeutics, Inc. (Nasdaq: ATOS) and Quantum Leap Healthcare Collaborative™ today announce that Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, will be evaluated in a new study arm of the ongoing I-SPY 2 clinical trial.
March 21, 2023
·
8 min read
Press Releases
Advantage Therapeutics Inc. Announces Formation of Klothea Bio, Inc. to Advance Research and Development of Klotho Protein for Age-Related Therapeutics
November 25, 2024
·
5 min read
Press Releases
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
November 26, 2024
·
9 min read
Press Releases
Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class Ophthalmic Medicines
December 12, 2024
·
4 min read
Press Releases
TransCode Therapeutics, Inc. Announces $8 Million Private Placement
November 27, 2024
·
4 min read
Press Releases
Versant Ventures Unveils Pep2Tango Therapeutics Inc.
November 21, 2024
·
4 min read
Business
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
Gain Therapeutics, Inc. announces that Matthias Alder has departed the Company in order to pursue other opportunities.
June 27, 2024
·
5 min read
1 of 70,367
Next
